Literature DB >> 21109068

Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.

David R Friend1, Gustavo F Doncel.   

Abstract

A significant number of women, especially in developing countries, need protection against more than one sexually transmitted infection (STIs), for instance HIV-1 and HSV-2, and family planning methods to prevent unwanted pregnancies. Dual protection technologies (DPTs; also known as multipurpose technologies) are designed to address two different indications with one product. Examples of DPTs are vaginal products capable of preventing transmission of HIV-1 in women while simultaneously providing contraceptive properties and a vaginal product capable of reducing HIV-1 transmission while preventing transmission of a second STI. DPTs can be categorized into three main approaches: 1) physical barriers, 2) chemical barriers, and 3) a combination of physical and chemical barriers. Examples of physical barriers are male and female condoms, diaphragms and cervical caps. Chemical barriers include use of a single drug with two mechanisms of action (viz., dual-activity compounds with microbicidal and contraceptive properties or activity against HIV-1 and a second STI pathogen such as HSV-2) or a combination of two drugs each targeted against separate mechanisms for achieving contraception and inhibition of HIV-1. Combinations of chemical and physical barriers are based on physical barriers such as a diaphragm along with a microbicide. Examples of each approach and current prototypes (such as vaginal gels and intravaginal rings) under development are described in this paper. Challenges facing development and regulatory approval of DPTs are also reviewed. This article forms part of a special supplement on a presentation covering DPTs, based on the symposium "Trends in Microbicide Formulations", held on 25 and 26 January 2010, Arlington, VA.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109068     DOI: 10.1016/j.antiviral.2010.09.005

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  25 in total

Review 1.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

2.  Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Cali Nguyen; Kathleen L Vincent; Massoud Motamedi; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

3.  Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

4.  Advances in vaginal drug delivery.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

Review 5.  Clinical evaluation of microbicide formulations.

Authors:  Kathleen M Morrow; Craig Hendrix
Journal:  Antiviral Res       Date:  2010-12       Impact factor: 5.970

Review 6.  Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.

Authors:  Florian Hladik; Gustavo F Doncel
Journal:  Antiviral Res       Date:  2010-12       Impact factor: 5.970

7.  Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.

Authors:  James M Smith; Priya Srinivasan; Ryan S Teller; Yungtai Lo; Chuong T Dinh; Patrick F Kiser; Betsy C Herold
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

Review 8.  Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.

Authors:  Jill M Steinbach
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

Review 9.  Translation of biomedical prevention strategies for HIV: prospects and pitfalls.

Authors:  Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

10.  Reproductive Life Goals: A Systematic Review of Pregnancy Planning Intentions, Needs, and Interventions Among Women Involved in U.S. Criminal Justice Systems.

Authors:  Emily Hoff; Zoe M Adams; Alyssa Grimshaw; Dawn A Goddard-Eckrich; Anindita Dasgupta; Sangini S Sheth; Jaimie P Meyer
Journal:  J Womens Health (Larchmt)       Date:  2020-06-23       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.